Amid sluggish sales and dueling lawsuits, Novartis bows out of Amgen partnership, slashes staff
When Novartis and Amgen got Aimovig approved in 2018, most migraine patients relied on decades-old, mildly effective pills to ease their headaches. Proven to reduce migraines by more than 50% in hard-to-treat patients, Aimovig was expected to quickly rake in over $1 billion per year.
In the three years since, though, a slew of rivals have entered: nearly identical treatments from Eli Lilly, Allergan, and Teva, alongside new oral options from Biohaven. Now, with competition tightening and relations between the two tense, Novartis is pulling out of the US market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.